Some lead stories that appeared on vaccine topics in past couple days.
As reported in Fierce Biotech, Novovax and Rovi end talks negating previously announced collaboration for VLP-based vaccines against the flu.
Fierce also reported Novartis licensed the hep C drug Debio 025 (alisporivir). This phase II drug was developed by Delbiopharm and represents a new class called cyclophilin inhibitors.
Novovax reported more positive data from its trivalent flu vaccine in healthy adults. See full article in Medical News Today.The New York Times reported poll results that majority of Americans do not plan to get an H1N1 vaccine, assume the pandemic is over, and feels the reporting was overblown.
Comments